<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00034359</url>
  </required_header>
  <id_info>
    <org_study_id>ACH443-003</org_study_id>
    <nct_id>NCT00034359</nct_id>
  </id_info>
  <brief_title>Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment Naive Adults With Chronic Hepatitis B Virus Infection</brief_title>
  <official_title>A Double-Blind, Randomized Trial of Antiviral Activity and Safety of 12 Weeks Oral Treatment With ACH-126,443 (Beta-L-Fd4C) in Treatment-Naive HBV-Infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achillion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achillion Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and anti-HBV activity of ACH-126, 443
      (beta-L-Fd4C) in comparison to lamivudine or placebo in treatment naive adults with chronic
      Hepatitis B infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of safety and antiviral activity of 3 dose levels of ACH-126, 443 vs. lamivudine
      and placebo over 12 weeks of treatment in the population described.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">79</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-126, 443 (beta-L-Fd4C)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults &gt;= 18 years of age

          -  Chronic HBV infection, known to be HbsAg positive &gt;= 6 months

          -  Plasma HBV DNA level &gt;= 100,000 copies/mL

          -  HBe-antigen positive

          -  HIV negative

          -  Basic hematologic and chemistry parameters within acceptable limits (defined in
             protocol

          -  No need for excluded medications

          -  Subjects of reproductive capability must utilize two approved forms of birth control,
             one of which must be barrier protection.

        Exclusion Criteria:

          -  HIV infection

          -  Hepatitis C co-infection

          -  Concurrent systemic antiviral treatment

          -  Previous antiviral treatment for HBV infection within 6 months prior to randomization
             or treatment with 3TC for more than 6 months at any time in the past

          -  Previous therapy with agents with significant systemic myelosuppressive or cytotoxic
             potential within 3 months of study start or the expected need for such therapy at
             study start

          -  Alcohol abuse

          -  Pregnancy or breast-feeding

          -  Inability to tolerate oral medication

          -  AST&gt;7.0 times the upper limit of normal

          -  ALT&gt;7.0 times the upper limit of normal

          -  Any clinical condition or prior therapy that, in the Investigators opinion, would make
             the subject unsuitable for the study or unable to comply with the dosing requirements

          -  Use of any investigational drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa M Dunkle, M.D.</last_name>
    <affiliation>Achillion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic of Gastroenterology</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foundation of Gastroenterology</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Center of Serbia, Institute of Infectious Disease</name>
      <address>
        <city>Belgrade</city>
        <country>Former Yugoslavia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Novi Sad</name>
      <address>
        <city>Novi Sad</city>
        <country>Former Yugoslavia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Former Yugoslavia</country>
  </location_countries>
  <link>
    <url>http://www.achillion.com</url>
  </link>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2002</study_first_submitted>
  <study_first_submitted_qc>April 26, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2002</study_first_posted>
  <last_update_submitted>February 18, 2014</last_update_submitted>
  <last_update_submitted_qc>February 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <keyword>E-antigen positive</keyword>
  <keyword>Treatment Naive Chronic Hepatitis B, Achillion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

